Roth Positive on Retrophin's (RTRX) Thiola Licensing Deal; Issues Commentary

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. AVGO
2. CDNS
3. SPY
4. META
5. JBLU
6. ANT
7. AAPL
8. INTC
9. SSD
10. ARTV

Go back to Roth Positive on Retrophin's (RTRX) Thiola Licensing Deal; Issues Commentary

Retrophin (RTRX) Enters Agreement for Thiola Marketing Rights in U.S.; Boosts Outlook

May 29, 2014 4:43 PM EDT

Retrophin, Inc. (NASDAQ: RTRX) announced that it has entered into a license agreement with Mission Pharmacal Company, a private company based in San Antonio, Texas, for U.S. marketing rights to Thiola (tiopronin). Financial terms of the agreement were not immediately disclosed.

Thiola® is approved by the U.S. Food and Drug Administration for the treatment of cystinuria, a rare genetic cystine... More